Source-grounded facts extracted from MoonLake Immunotherapeutics's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MoonLake Immunotherapeutics shareholders approved Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan.
“Proposal 4. Approval of an Amendment and Restatement of the 2022 Equity Incentive Plan 50,599,032 498,186 14,146 10,761,142”
MoonLake Immunotherapeutics shareholders approved Advisory Vote on Executive Compensation.
“Proposal 3. Advisory Vote on Executive Compensation 50,365,168 731,158 15,038 10,761,142”
MoonLake Immunotherapeutics shareholders approved Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor.
“Proposal 2. Ratification, by ordinary resolution, of Baker Tilly US, LLP as Independent Auditor 61,831,463 17,522 23,521 0”
MoonLake Immunotherapeutics shareholders approved Election of Class I Director Nominee.
“At the Annual Meeting, the Class I director nominee was elected and the other proposals voted on were approved. The final voting results are set forth below: Votes For Votes Withheld Broker Non-Votes Proposal 1. Election of the Class I Director Nominee ● Spike Loy 47,222,233 3,889,131 10,761,142”
MoonLake Immunotherapeutics entered into Capacity Agreement with Vetter Pharma International GmbH (effective 2026-05-22).
“Also on May 22, 2026, the Company and Vetter entered into a Capacity Agreement (the “Vetter Capacity Agreement”), under which the Company is required to provide Vetter with its aggregate demand for a product for a certain period, with the annual demands for the initial term of such forecast constituting a binding capacity reservation commitment (the “MoonLake Commitment”).”
MoonLake Immunotherapeutics entered into Master Commercial Supply Agreement with Vetter Pharma International GmbH (effective 2026-05-22).
“On May 22, 2026, MoonLake Immunotherapeutics (the “Company”) entered into a Master Commercial Supply Agreement (the “Vetter MCSA”) with Vetter Pharma International GmbH (“Vetter”).”
MoonLake Immunotherapeutics reported financial results for first quarter of 2026.
“Today, MoonLake also reported its financial results for the first quarter of 2026.”
MoonLake Immunotherapeutics incurred term loan of $25.0 million with Hercules Capital, Inc., as administrative agent and collateral agent.
“As described below, after giving effect to a $25.0 million draw on the Amendment Closing Date, the remaining tranches under the Amended Loan and Security Agreement provide for an aggregate principal amount of up to $400.0 million of potential future funding.”
MoonLake Immunotherapeutics amended First Amendment to Loan and Security Agreement (Amended Loan and Security Agreement) with Hercules Capital, Inc. valued at Up to $400.0 million of potential future funding; aggregate principal amount of $500.0 million acros (effective 2026-02-20).
“On February 20, 2026 (the "Amendment Closing Date"), MoonLake Immunotherapeutics (the "Company"), as a guarantor, entered into a first amendment to loan and security agreement (the loan and security agreement, as so amended, the "Amended Loan and Security Agreement") with its subsidiary, MoonLake Immunotherapeutics AG, as borrower, the other guarantors party thereto, the lenders party thereto (the "Lenders"), and Hercules Capital, Inc., as the administrative agent and collateral agent (the "Agent") for itself and the Lenders, pursuant to which the parties agreed to amend the loan and security agreement dated March 31, 2025 to, among other things, modify the available tranches, milestone dates and financial covenants.”
MoonLake Immunotherapeutics incurred term loan of $300.0 million is fully committed with Hercules Capital, Inc. at prime rate as reported in The Wall Street Journal plus 1.45% and (ii) 8.45% maturing April 1, 2030.
“The Loan and Security Agreement provides for a non-dilutive term loan facility of up to an aggregate principal amount of $500.0 million, of which $300.0 million is fully committed subject to achievement of milestones (the “Credit Facility”), consisting of (a) a first tranche consisting of term loans in an aggregate principal amount of $75.0 million which was fully funded on the Closing Date”
MoonLake Immunotherapeutics reported financial results for the quarter ended March 31, 2024.
“MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.”
MoonLake Immunotherapeutics reported the quarter and fiscal year ended December 31, 2023 results: net income $44.1 million.
“MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.”
MoonLake Immunotherapeutics reported financial results for the quarter ended September 30, 2023.
“MoonLake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.”
MoonLake Immunotherapeutics reported financial results for the quarter ended June 30, 2023.
“Moonlake Immunotherapeutics (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.”
MoonLake Immunotherapeutics entered into Underwriting Agreement with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters valued at $460 million (effective 2023-06-27).
“On June 27, 2023, MoonLake Immunotherapeutics (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with SVB Securities LLC and Guggenheim Securities LLC as the representatives of the underwriters named therein (the “Underwriters”), to issue and sell 8,000,000 Class A ordinary shares, par value per share $0.0001 (the “Firm Shares”), at a public offering price of $50.00 per share (the “Offering”).”
MoonLake Immunotherapeutics reported the fourth quarter and year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $64.5 million.
“MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update”
Dr. Andrew J. Phillips resigned as Officer at MoonLake Immunotherapeutics.
“In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.”
Bihua Chen resigned as Officer at MoonLake Immunotherapeutics.
“In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.”
John Schmid resigned as Director at MoonLake Immunotherapeutics.
“In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.”
Will Lewis resigned as Director at MoonLake Immunotherapeutics.
“In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.”
Dr. Nancy Chang resigned as Director at MoonLake Immunotherapeutics.
“In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.”
Bihua Chen resigned as Director at MoonLake Immunotherapeutics.
“In connection with the Closing, Bihua Chen, Dr. Nancy Chang, Will Lewis and John Schmid resigned as directors of Helix, and Bihua Chen and Dr. Andrew J. Phillips resigned as officers of Helix.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.